rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    VIR
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      AMD, Dell among market cap stock movers on Friday
      Nov 13Investing.comAMDVIRDELL
      Vir Biotechnology Shares Drop as Biotech Firm Moves Ahead With Stock Sale
      Nov 13Yahoo FinanceVIR
      Vir Biotechnology stock tumbles on $150M share offering
      Nov 13Investing.comVIR
      Why Is Vir Biotechnology Stock Falling Friday?
      Nov 13BenzingaVIR
      Why is Vir Biotechnology stock tumbling today?
      Nov 13Investing.comVIR
      Vir Biotechnology Announces Pricing of Public Offering of Common Stock
      Nov 13Yahoo FinanceVIR
      Vir Biotechnology announces public stock offering
      Nov 12Investing.comVIR
      Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48
      Nov 10Yahoo FinanceVIR
      Vir Biotechnology Stock: Fairly Valued After Phase 3 Success? (NASDAQ:VIR)

      Vir Biotechnology remains a Buy after flawless Phase 3 ECLIPSE 1 results and a major new Gilead partnership. Read more on VIR stock here.

      Nov 10Seeking AlphaVIR
      Is Vir Biotechnology (VIR) A Bargain After Its Hepatitis Delta Phase 3 Win?
      Nov 10Yahoo FinanceVIR
      Is Vir Biotechnology (VIR) Overvalued After Its 127% Run?
      Nov 9Yahoo FinanceVIR
      Vir Biotechnology (VIR) Says Its Hepatitis Delta Therapy Met All Phase 3 Endpoints
      Nov 9Yahoo FinanceVIR
      Why Is Vir Biotechnology Stock Trading Higher Today? - Vir Biotechnology (NASDAQ:VIR)
      Nov 9BenzingaVIR
      Vir Biotechnology reports positive Phase 3 trial results for hepatitis delta treatment
      Nov 9Investing.comVIR
      Wall Street Analysts Predict a 75.59% Upside in Vir Biotechnology (VIR): Here's What You Should Know
      Nov 9Yahoo FinanceVIR
      Vir Stock Soars After Late-Stage Trial Win. Why Biotech Could Be Headed for the FDA
      Nov 9Yahoo FinanceVIR
      Why is Vir Biotechnology stock surging today?
      Nov 9Investing.comVIR
      Vir Biotechnology stock jumps 22% after hepatitis delta Phase 3 trial success
      Nov 9Investing.comVIR
      12 Health Care Stocks Moving In Monday's Pre-Market Session
      Nov 9BenzingaMXCTVIR
      VIR Stock Soars Over 10% Overnight, Eyes Best Year Ever — Hepatitis Win Sparks Buyout Buzz And Bigger Bullish Bets
      Nov 9Yahoo FinanceVIR
      Vir Biotechnology reports positive hepatitis results, early signs of possible cure (VIR:NASDAQ)

      Vir hepatitis delta combo hit its phase 3 goal, with phase 2 showing lasting viral suppression.

      Nov 8Seeking AlphaVIR
      Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta
      Nov 8Yahoo FinanceVIR
      Vir Biotechnology Stock Gets Focus As Phase 3 Hepatitis Delta Data Head To AASLD
      Nov 7Yahoo FinanceVIR
      Vir Biotechnology to present hepatitis delta trial data
      Nov 5Investing.comVIR
      Vir Biotechnology EVP Vanina de Verneuil sells $41,938 in company stock
      Nov 5Investing.comVIR
      Vir Biotechnology Inc (VIR) (Q3 2026) Earnings Call Highlights: Hepatitis Delta Data on Deck ...
      Nov 5Yahoo FinanceVIR
      Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates
      Nov 4Yahoo FinanceVIR
      Vir Biotechnology Q3 2026 Earnings Call Transcript
      Nov 4BenzingaVIR
      Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results
      Nov 4Yahoo FinanceVIR
      Vir Biotechnology earnings faces test as HDV, oncology trials loom
      Nov 4Investing.comVIR
      Earnings To Watch: Vir Biotechnology Inc (VIR) Q3 2026 -- GF Value Sees 111% Upside
      Nov 3Yahoo FinanceVIR
      Vir Biotechnology stock hits 52-week high at $12.02
      Oct 29Investing.comVIR
      Vir Biotechnology appoints Suzanne Topalian to board of directors
      Oct 28Investing.comVIR
      Vir Biotechnology appoints cancer expert to board
      Oct 28Investing.comVIR
      Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors
      Oct 28Yahoo FinanceVIR
      Vir Biotechnology: A Big Pharma Collaboration And 2 Clinical Catalysts This Quarter (VIR)
      Oct 27Seeking AlphaVIR
      Is Vir Biotechnology (VIR) Undervalued On Its Gilead Oncology Deal?
      Oct 27Yahoo FinanceGILDVIR
      Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results
      Oct 21Yahoo FinanceVIR
      Could Vir Biotechnology (VIR) Be Above Fair Value After Recent Pipeline News?
      Oct 17Yahoo FinanceVIR
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Vir Biotechnology Inc (VIR-Q) from The Globe and Mail including charting and trades.

      Oct 15The Globe and MailVIR
      Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers
      Oct 15Yahoo FinanceVIR
      Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments - Gilead Sciences (NASDAQ:GILD), Vir Bio

      Vir Biotechnology and Gilead collaborate on novel T-cell engagers for solid tumors in a deal worth up to $1.87 billion, plus royalties.

      Oct 14BenzingaGILDVIR
      Vir Biotechnology partners with Gilead on cancer therapies
      Oct 14Investing.comVIR
      Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
      Oct 14Yahoo FinanceVIR
      Vir Biotechnology, Gilead Sciences to Develop Dual-Masked T-Cell Engagers for Solid Tumors
      Oct 14Yahoo FinanceGILDVIR
      Vir jumps on Gilead licensing deal worth up to $1.9B for cancer drugs
      Oct 14Seeking AlphaGILDVIR
      Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
      Oct 14Yahoo FinanceGILDVIR
      Vir Biotechnology stock hits 52-week high at 11.96 USD
      Oct 9Investing.comVIR
      Vir Biotechnology's VIR-5500 Gets FDA Fast Track Designation for Prostate Cancer
      Oct 8Yahoo FinanceVIR
      H.C. Wainwright raises Vir Biotechnology price target to $22
      Oct 8Investing.comVIR

      This is the newest page. Registered accounts read further back.